Similarly, the DNAJB1-PRKACA fusion was observed in more than 90% of fibrolamellar liver carcinoma30, which accounted for 22.5% of liver cancers in AYAs but only 0.1% in OAs. Here, DNAJB1 is linked to liver cancer.